Pharma News

Bayer has announced promising new findings showing that finerenone, its non-steroidal mineralocorticoid receptor antagonist, significantly lowers the risk of chronic kidney disease (CKD) progression and major cardiovascular complications across a broad range of patients living with CKD. The latest results were presented during the 63rd European Renal Association (ERA) Congress.

Axsome Therapeutics has announced the resolution of all remaining patent litigation related to its wake-promoting medicine SUNOSI (solriamfetol), bringing an end to a series of legal disputes with generic drug manufacturers seeking U.S. market entry.

Researchers have identified four promising blood-based metabolites that may help distinguish individuals with latent tuberculosis infection (LTBI) from those without infection, according to a new study published in BIO Integration. The findings provide fresh insights into the metabolic changes associated with latent tuberculosis and could support the development of improved diagnostic approaches in the future.

Bharat Biotech's plans to advance its tuberculosis vaccine candidate MTBVAC (BBV169) into Phase III clinical trials have been put on hold after the Subject Expert Committee (SEC) on Vaccines sought additional data and protocol revisions before granting further approval.

The proposal was reviewed during the meeting of the SEC - Vaccine held on May 28, 2026. The company presented its Phase III clinical trial protocol along with an interim report from the ongoing Phase II clinical study.

India’s drug regulator has issued a fresh reminder to pharmaceutical manufacturers and other stakeholders regarding the mandatory implementation of pharmacovigilance (PV) systems under the provisions of the Drugs and Cosmetics Act, 1940 and related rules.

Glenmark Pharmaceuticals Ltd. has announced that its U.S.-based subsidiary, Glenmark Pharmaceuticals Inc., USA, has launched Lacosamide Injection USP 200 mg/20 mL (10 mg/mL) Single-Dose Vials in the United States market. The product is the generic equivalent of Vimpat Injection marketed by UCB Inc. and is indicated for the treatment of seizures associated with epilepsy.